#USA #Telix #ImaginAb #Inglewood #CD8 ImmunoPET

ImaginAb's Innovative Technology Platform Acquired by Telix

On January 23, 2025, ImaginAb, Inc. announced a significant transaction in the biopharmaceutical domain, selling its suite of next-generation therapeutic candidates, exclusive technology platform, and protein discovery facility to Telix Pharmaceuticals Limited (ASX: TLX; Nasdaq: TXL). This acquisition aims to bolster Telix's therapeutic asset discovery capabilities via advanced biologics technology.

Following the completion of this deal, ImaginAb will focus on its flagship imaging product, CD8 ImmunoPET, which is currently undergoing Phase 2 clinical trials. This standout imaging technology has garnered multiple licenses from renowned pharmaceutical and biotechnology companies, significantly in the field of oncology. Additionally, ImaginAb will also enhance its partnership to advance its prostate cancer imaging agent, which is being evaluated in Phase 2 clinical trials, focusing on surgical resection support.

Dr. Anna Wu, the founder of ImaginAb, expressed her enthusiasm regarding the acquisition, stating, “We are thrilled that Telix recognizes the potential of our innovative biological technology platform, which enables them to explore new pathological areas through advanced radiotherapeutic technology. These radiopharmaceutical agents reflect substantial efforts and resources from our scientific team.” She further commended the entire ImaginAb team for reaching this pivotal milestone, underscoring the credibility and innovation of the company’s minicorp platform.

Dr. Wu added, “With the sale of our radiopharmaceutical platform, ImaginAb will continue developing its CD8 platform. We are encouraged by the integration of our technology into numerous clinical trials across the immuno-oncology sector by various pharmaceutical and biotech firms.”

The financial advisory role for ImaginAb in this transaction was handled by Jefferies LLC and Stifel, Nicolaus & Company, Incorporated.

About ImaginAb, Inc.

ImaginAb, Inc. is a revenue-generating global clinical-stage biotech company focused on developing the next generation of radiopharmaceutical products and imaging agents. These proprietary products feature modified antibodies that retain the specificity of full-length antibodies while being biologically inert within the body. Utilizing widely available positron emission tomography (PET) and optical imaging technologies, these new targeting agents are designed to bind selectively to surface cell targets.

ImaginAb's operations are backed by leading venture capital and strategic companies such as Adage Capital, The Cycad Group, Norgine Ventures, Innoviva, and pharma giants like Merck (MSD), among others. More details about ImaginAb's portfolio and technology can be found on their website at www.imaginab.com.

About CD8 ImmunoPET

The CD8 ImmunoPET technology utilizes 89Zr (zirconium Zr 89 crefmirlimab berdoxam) labeled minicorps that bind to the CD8 receptor found on human T cells. This technology serves for non-invasive and quantitative imaging of CD8+ T cells in patients. Given the vital role of CD8+ T cells in the immune response against tumor cells induced by immunotherapy, quantifying these cells could provide critical insights into a patient’s immune status, gauge the efficacy of immunotherapies, and predict patient outcomes.

About PSMA Optical Imaging

The PSMA optical imaging agent (IR-800 IAB2) is a fluorescence-labeled minicorp that specifically binds to PSMA receptors present on cancer cells, particularly prostate cancer cells. This agent is utilized for non-invasive PET imaging of PSMA+ cells in patients undergoing surgical procedures to excise cancerous tissues. Therefore, imaging PSMA+ cells assists clinicians in identifying and effectively resecting cancerous tissues during surgery.

With the sale to Telix, ImaginAb is set to pave new pathways in therapeutic discovery, reinforcing its commitment to advancing medical imaging and therapeutics.